One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology
Z.Z.N. Yiu K.J. Mason C.H. Smith C.E.M. Griffiths on behalf of the BADBIR Study Group
doi : 10.1111/bjd.19536
Volume183, Issue6 December 2020 Pages 981-983
New brodalumab psoriasis outcome data suggests that intermittent treatment is as effective as continuous dosing. Is it time to re?evaluate our treatment regimens?
P. Babakinejad P.J. Hampton
doi : 10.1111/bjd.19329
Volume183, Issue6 December 2020 Pages 984-985
Linked Article: Papp et al. Br J Dermatol 2020; 183:1037–1048.
Global trends in melanoma mortality differ by sex and age
C.M. Olsen
doi : 10.1111/bjd.19166
Volume183, Issue6 December 2020 Pages 985-986
Linked Article: Yang et al. Br J Dermatol 2020; 183:1056–1064.
A new self?reported measure of disease severity of scalp hair loss in alopecia areata
F. Rencz
doi : 10.1111/bjd.19230
Volume183, Issue6 December 2020 Pages 986-987
Linked Article: Wyrwich et al. Br J Dermatol 2020; 183:1065–1072.
Systemic treatment in atopic dermatitis after 2018: from experienced?based treatment to evidence?based treatment?
M. de Bruin?Weller
doi : 10.1111/bjd.19227
Volume183, Issue6 December 2020 Pages 987-988
Linked Article: Vermeulen et al. Br J Dermatol 2020; 183:1073–1082.
What are the barriers to physical activity in patients with chronic plaque psoriasis?
P. Jarrett
doi : 10.1111/bjd.19209
Volume183, Issue6 December 2020 Pages 988-989
Linked Article: Auker et al. Br J Dermatol 2020; 183:1094–1102.
The epidemiology of hidradenitis suppurativa
John R. Ingram
doi : 10.1111/bjd.19435
Volume183, Issue6 December 2020 Pages 990-998
Aetiology and pathogenesis of hidradenitis suppurativa
K. Wolk O. Join?Lambert R. Sabat
doi : 10.1111/bjd.19556
Volume183, Issue6 December 2020 Pages 999-1010
Ex vivo confocal microscopy: revolution in fast pathology in dermatology
J. Malvehy J. Pérez?Anker A. Toll R. Pigem A. Garcia L.L. Alos S. Puig
doi : 10.1111/bjd.19017
Volume183, Issue6 December 2020 Pages 1011-1025
Systematic review of the efficacies and adverse effects of treatments for pityriasis lichenoides
F. Jung C. Sibbald M. Bohdanowicz J.R. Ingram V. Piguet
doi : 10.1111/bjd.18977
Volume183, Issue6 December 2020 Pages 1026-1032
Assessing the effect of clinical trial evidence and anecdote on caregivers’ willingness to use corticosteroids: a randomized controlled trial: a critical appraisal
A. Brown Z. Tsianou H.C. Williams
doi : 10.1111/bjd.18956
Volume183, Issue6 December 2020 Pages 1033-1036
Long?term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE?1)*
K. Papp A. Menter C. Leonardi J. Soung S. Weiss R. Pillai A. Jacobson
doi : 10.1111/bjd.19132
Volume183, Issue6 December 2020 Pages 1037-1048
Statins may reduce disease recurrence in patients with ulcerated primary melanoma
L.A. von Schuckmann K. Khosrotehrani R. Ghiasvand M.C.B. Hughes J.C. van der Pols M. Malt B.M. Smithers A.C. Green
doi : 10.1111/bjd.19012
Volume183, Issue6 December 2020 Pages 1049-1055
Trends in malignant melanoma mortality in 31 countries from 1985 to 2015*
D.D. Yang J.D. Salciccioli D.C. Marshall A. Sheri J. Shalhoub
doi : 10.1111/bjd.19010
Volume183, Issue6 December 2020 Pages 1056-1064
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata
K.W. Wyrwich H. Kitchen S. Knight N.V.J. Aldhouse J. Macey F.P. Nunes Y. Dutronc N. Mesinkovska J.M. Ko B.A. King
doi : 10.1111/bjd.19024
Volume183, Issue6 December 2020 Pages 1065-1072
The European TREatment of ATopic eczema (TREAT) Registry Taskforce survey: prescribing practices in Europe for phototherapy and systemic therapy in adult patients with moderate?to?severe atopic eczema
F.M. Vermeulen L.A.A. Gerbens J. Schmitt M. Deleuran A.D. Irvine K. Logan W. Ouwerkerk C. Vestergaard C. Flohr P.I. Spuls on behalf of the international TREAT Registry Taskforce
doi : 10.1111/bjd.18959
Volume183, Issue6 December 2020 Pages 1073-1082
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing
E. Del Duca J. Ruano Ruiz A.B. Pavel R.D. Sanyal T. Song J. Gay?Mimbrera N. Zhang Y.D. Estrada X. Peng Y. Renert?Yuval R.G. Phelps R. Paus J.G. Krueger E. Guttman?Yassky
doi : 10.1111/bjd.19040
Volume183, Issue6 December 2020 Pages 1083-1093
What are the barriers to physical activity in patients with chronic plaque psoriasis?
L. Auker L. Cordingley S.R. Pye C.E.M. Griffiths H.S. Young
doi : 10.1111/bjd.18979
Volume183, Issue6 December 2020 Pages 1094-1102
The limitations of case reports in professional development
R.I. Yesudian P. Yesudian P.D. Yesudian
doi : 10.1111/bjd.19469
Volume183, Issue6 December 2020 Pages 1103-1104
First? and third?generation epidermal growth factor receptor inhibitors mediate distinct phosphoprotein signalling networks: implications for adverse dermatological reactions
C. Vasavda B.K. Ho D.Y. Zhang K.A. Williams B.H. Kaffenberger S.G. Kwatra M.M. Kwatra
doi : 10.1111/bjd.19263
Volume183, Issue6 December 2020 Pages 1105-1107
Burnout in psychodermatology: results from a European survey
M.?A. Gkini K. Hussain R. Taylor A. Bewley
doi : 10.1111/bjd.19308
Volume183, Issue6 December 2020 Pages 1107-1108
Coinheritance of naevoid basal cell carcinoma syndrome and neurofibromatosis type 1 associated with an exceptional spectrum of tumours
S.J. Ghadiri P. Brennan E. Calonje A.J. Carmichael N. Rajan
doi : 10.1111/bjd.19324
Volume183, Issue6 December 2020 Pages 1108-1110
External validation of a model to predict risk of keratinocyte skin cancer after renal transplantation in a Western European cohort
E.J. Verhage P.J. Nelemans S.M.J. van Kuijk M.H.L. Christiaans N.W.J. Kelleners?Smeets
doi : 10.1111/bjd.19326
Volume183, Issue6 December 2020 Pages 1110-1112
Bacterial and fungal microbiome characterization in patients with rosacea and healthy controls
R. Wang M. Farhat J. Na R. Li Y. Wu
doi : 10.1111/bjd.19315
Volume183, Issue6 December 2020 Pages 1112-1114
Assessing the quality of intervention reporting in dermatology randomized controlled trials using the TIDieR checklist
R. Bindernagel C. Cook C. Wayant S. Jellison M. Vassar
doi : 10.1111/bjd.19382
Volume183, Issue6 December 2020 Pages 1114-1115
Development and efficacy of a nested real?time quantitative polymerase chain reaction to identify the cytochrome c oxidase subunit 1 gene of Sarcoptes scabiei var. hominis for diagnosis and monitoring of ordinary scabies
J.K. Kim E.J. Chun S.Y. Yang K.S. Kim S.S. Kim C.W. Kim
doi : 10.1111/bjd.19340
Volume183, Issue6 December 2020 Pages 1116-1117
Efficacy and safety of topical resorcinol 15% as long?term treatment of mild?to?moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance
E. Molinelli V. Brisigotti , O. Simonetti , A. Campanati , C. Sapigni , G.M. D’Agostino , A. Giacchetti , C. Cota , A. Offidani
doi : 10.1111/bjd.19337
Volume183, Issue6 December 2020 Pages 1117-1119
Effectiveness of a stop smoking service in reducing cigarette smoking in patients referred from a National Health Service dermatology centre
L.F. Soriano H. Poole J.R. Ingram R.A. Abbott
doi : 10.1111/bjd.19378
Volume183, Issue6 December 2020 Pages 1119-1121
Incidence and outcome of Spitzoid tumour of unknown malignant potential (STUMP): an analysis of cases in the Netherlands from 1999 to 2014
C.G.H. Ruijter W. Ouwerkerk E.H. Jaspars R. van Doorn R.M. Luiten M.W. Bekkenk D.C.K.S. Tio
doi : 10.1111/bjd.19383
Volume183, Issue6 December 2020 Pages 1121-1123
Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis: abridged Cochrane review
F. Peinemann M. Harari S. Peternel T. Chan D. Chan A.M. Labeit T. Gambichler
doi : 10.1111/bjd.19385
Volume183, Issue6 December 2020 Pages 1123-1124
Clinical predictive factors of unresponsiveness to omalizumab in patients with chronic spontaneous urticaria
J. Castagna L. Bernard F. Hacard F. Delcroix A.?S. Darrigade J.?F. Nicolas E. Decullier A. Nosbaum F. Bérard
doi : 10.1111/bjd.19312
Volume183, Issue6 December 2020 Pages 1124-1126
Diagnostic and therapeutic differences between immune checkpoint inhibitor?induced and idiopathic bullous pemphigoid: a cross?sectional study
G.E. Molina K.L. Reynolds S.T. Chen
doi : 10.1111/bjd.19313
Volume183, Issue6 December 2020 Pages 1126-1128
Dermatological signs lead to discovery of mosaic ACTB variants in segmental odontomaxillary dysplasia
S. Polubothu D. Abdin M. Barysch A. Thomas N. Bulstrode R. Evans L. Solman J. Obwegeser R.C. Hennekam L. Weibel A. Calder N. Di Donato V.A. Kinsler
doi : 10.1111/bjd.19339
Volume183, Issue6 December 2020 Pages 1128-1130
Epidermal growth factor receptor inhibitor therapy?associated erythema dyschromicum perstans?like eruption: a case series
K.J. Ransohoff S.B. Pugliese L.C. Zaba K.E. Rieger B.Y. Kwong
doi : 10.1111/bjd.19396
Volume183, Issue6 December 2020 Pages 1130-1132
Active vs. standard sun protection in patients with melanoma stage I or II: a randomized controlled feasibility trial assessing compliance with sun protection and quality of life
H. Goeth M. Koller M.?V. Hegemann K. Drexler F. Zeman G. Huppertz M. Berneburg T. Maisch
doi : 10.1111/bjd.19395
Volume183, Issue6 December 2020 Pages 1132-1134
Comparison of registered and published outcomes in randomized trials in dermatology journals: a cross?sectional analysis
L. Steele A. Livesey A. Hong J. Thomson C. Flohr
doi : 10.1111/bjd.19397
Volume183, Issue6 December 2020 Pages 1134-1136
Frontal fibrosing alopecia: a descriptive cross?sectional study of 711 cases in female patients from the UK
S.M. McSweeney E.A.A. Christou N. Dand A. Boalch S. Holmes M. Harries I. Palamaras F. Cunningham G. Parkins M. Kaur P. Farrant A. McDonagh A. Messenger J. Jones V. Jolliffe I. Ali M. Ardern?Jones C. Mitchell N. Burrows R. Atkar C. Banfield A. Alexandroff C. Champagne H.L. Cooper G.K. Patel A. Macbeth M. Page A. Bryden M. Mowbray S. Wahie K. Armstrong N. Cooke M. Goodfield I. Man D. de Berker G. Dunnil A. Takwale A. Rao T.?W. Siah R. Sinclair M.S. Wade K. Bhargava D.A. Fenton J.A. McGrath C. Tziotzios
doi : 10.1111/bjd.19399
Volume183, Issue6 December 2020 Pages 1136-1138
Sustained improvement of surgical scar appearance 1 year after early intervention with nonablative fractional laser treatment: a randomized controlled split?wound trial
G.L. Grove C.A. Banzhaf U. Paasch A. Nast M. Haedersdal K.E. Karmisholt
doi : 10.1111/bjd.19400
Volume183, Issue6 December 2020 Pages 1138-1140
Cutaneous signs in SARS?CoV?2 infection: a plea for more rigorous peer review in the time of COVID?19
H. Kittler P. Tschandl W. Weninger
doi : 10.1111/bjd.19429
Volume183, Issue6 December 2020 Pages 1140-1142
Paucity of COVID?19 dermatology literature from low? and middle?income countries
R.S. Pendse B.L. Schwartz J.L. Jia E.E. Bailey
doi : 10.1111/bjd.19505
Volume183, Issue6 December 2020 Pages 1142-1143
Skin disease case mix in the early 1920s: diagnoses prevalent at the time of the founding of the British Association of Dermatologists
D.J. Gawkrodger J.A.A. Hunter
doi : 10.1111/bjd.19506
Volume183, Issue6 December 2020 Pages 1144-1145
Co?reactivation of the human herpesvirus alpha subfamily (herpes simplex virus?1 and varicella zoster virus) in a critically ill patient with COVID?19
R. Xu Y. Zhou L. Cai L. Wang J. Han X. Yang J. Chen J. Chen C. Ma L. Shen
doi : 10.1111/bjd.19484
Volume183, Issue6 December 2020 Pages 1145-1147
The need for dose–response studies: time for a reminder?
S. Shuster
doi : 10.1111/bjd.19419
Volume183, Issue6 December 2020 Pages 1148-1148
Linked Article: Heetfeld et al. Br J Dermatol 2020; 183:139–145.
‘The need for dose–response studies: time for a reminder?’ – reply from the authors
T. Buhl J. Geier
doi : 10.1111/bjd.19423
Volume183, Issue6 December 2020 Pages 1148-1149
Linked Articles: Shuster. Br J Dermatol 2020; 183:1148. Heetfeld et al. Br J Dermatol 2020; 183:139–145
Response to ‘The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population?based matched cohort study in Korea’
J.W. Choi E.?S. Lee
doi : 10.1111/bjd.19464
Volume183, Issue6 December 2020 Pages 1149-1150
Linked Article: Kim et al. Br J Dermatol 2020; 182:907–915.
Response to ‘The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population?based matched cohort study in Korea’ – reply from the authors
H.S. Kim H.S. Ahn
doi : 10.1111/bjd.19465
Volume183, Issue6 December 2020 Pages 1150-1151
Linked Articles: Choi and Lee. Br J Dermatol 2020; 183:1149–1150; Kim et al. Br J Dermatol 2020; 182:907–915.
Negative tests for SARS?CoV?2 infection do not rule out its responsibility for chilblains
G. Battesti V. Descamps
doi : 10.1111/bjd.19483
Volume183, Issue6 December 2020 Pages 1151-1151
No abstract is available for this article.
Negative tests for SARS?CoV?2 infection do not rule out its responsibility for chilblains: reply from the authors
L. Le Cleach S. Fourati E. Sbidian M. Beylot?Barry
doi : 10.1111/bjd.19486
Volume183, Issue6 December 2020 Pages 1151-1152
No abstract is available for this article.
Chilblains and COVID?19: why SARS?CoV?2 endothelial infection is questioned
M. Baeck D. Hoton L. Marot A. Herman
doi : 10.1111/bjd.19489
Volume183, Issue6 December 2020 Pages 1152-1153
Linked Article: Colmenero et al. Br J Dermatol 2020; 183:729–737.
Chilblains and COVID?19: why SARS?CoV?2 endothelial infection is questioned. Reply from the authors
I. Colmenero C. Santonja M. Alonso?Ria?o D. Andina J.L. Rodr?guez?Peralto L. Requena A. Torrelo
doi : 10.1111/bjd.19491
Volume183, Issue6 December 2020 Pages 1153-1154
Linked Articles: Baeck et al. Br J Dermatol 2020; 183:1152–1153. Colmenero et al. Br J Dermatol 2020; 183:729–737
Response to ‘No evidence of SARS?CoV?2 infection by polymerase chain reaction or serology in children with pseudo?chilblain’
S. Recalcati S. Tonolo F. Luzzaro F. Fantini
doi : 10.1111/bjd.19493
Volume183, Issue6 December 2020 Pages 1154-1156
Linked Article: Caselli et al. Br J Dermatol 2020; 183:784–785.
Response to ‘No evidence of SARS?CoV?2 infection by polymerase chain reaction or serology in children with pseudo?chilblain’. Reply from the authors
D. Caselli M. Chironna D. Loconsole M. Aric?
doi : 10.1111/bjd.19563
Volume183, Issue6 December 2020 Pages 1156-1157
Linked Articles: Recalcati et al. Br J Dermatol 2020; 183:1154–1156; Caselli et al. Br J Dermatol 2020; 183:784–785. Colmenero et al. Br J Dermatol 2020; 183:729–737.
Profound consequences of hidradenitis suppurativa: a review
?. Matusiak
doi : 10.1111/bjd.16603
Volume183, Issue6 December 2020 Pages e171-e177
Current and future treatment of hidradenitis suppurativa
K.R. van Straalen S. Schneider?Burrus E.P. Prens
doi : 10.1111/bjd.16768
Volume183, Issue6 December 2020 Pages e178-e187
Pre?emptive intra?auricular electrosurgical resurfacing of cylindromas to prevent conductive deafness in CYLD cutaneous syndrome
J. Langtry N. Rajan
doi : 10.1111/bjd.19331
Volume183, Issue6 December 2020 Pages e188-e188
Complete response of metastatic pleomorphic dermal sarcoma to anti?PD?1 therapy
O. Klein C. McTigue Z.W. Wong D.B. Syme D.J. Hunter?Smith
doi : 10.1111/bjd.19309
Volume183, Issue6 December 2020 Pages e189-e189
A case of cowpox virus infection in the UK occurring in a domestic cat and transmitted to the adult male owner
C. Haddadeen M. Van Ouwerkerk T. Vicek A. Fityan
doi : 10.1111/bjd.19319
Volume183, Issue6 December 2020 Pages e190-e190
Why don’t people with psoriasis take enough exercise?
doi : 10.1111/bjd.19581
Volume183, Issue6 December 2020 Pages e191-e191
Psoriasis is a chronic skin condition which causes red, scaly patches and affects around 2% of the population. People with psoriasis are more likely than others to suffer cardiovascular disease (e.g. heart attack or stroke). It is well known that regular physical exercise reduces the risk of cardiovascular disease, but, worryingly, people with psoriasis take less exercise than most people.
A study examining if long?term use of a biologic, including stopping and restarting, is safe and effective in people with psoriasis
doi : 10.1111/bjd.19582
Volume183, Issue6 December 2020 Pages e192-e192
Psoriasis is a chronic disease that causes itchy, scaly patches on the skin and affects up to 3% of people worldwide. People with moderate?to?severe psoriasis may be prescribed injectable medications called biologics. However, people with psoriasis may need to receive medication for an extended period of time, so it is important to know if biologics keep skin clear and are safe to use long?term. Further, people with psoriasis sometimes stop and restart treatments, so it is important to understand if biologics keep skin clear even after a gap in treatment.
Melanoma death rates in 31 countries between 1985 and 2015
doi : 10.1111/bjd.19583
Volume183, Issue6 December 2020 Pages e193-e193
Malignant melanoma causes the highest number of deaths among skin cancers. In the UK, it is estimated that 86% of melanoma cases are preventable. Strategies have been implemented in many countries to try to improve the prevention of melanoma, as well as its diagnosis and treatment. Our study aimed to explore the patterns of mortality, or deaths, caused by melanoma over the past few decades, as this information may help us assess whether the strategies implemented thus far have been effective.
An overview of prescribing practices in Europe for light therapy and systemic therapy in adults with moderate?to?severe atopic eczema
doi : 10.1111/bjd.19584
Volume183, Issue6 December 2020 Pages e194-e194
Atopic eczema (AE) is a disease that causes redness and itch on the skin. It affects 1?5% of adults in Europe. For many years dermatologists have had access to few therapies for patients with moderate?to?severe AE.
Hidradenitis suppurativa: how common is the condition and what is it linked to?
doi : 10.1111/bjd.19585
Volume183, Issue6 December 2020 Pages e195-e195
Hidradenitis suppurativa, shortened to HS, is a long?term disease causing painful boils in skin creases such as the armpits and groin. There are no standard tests to confirm the diagnosis and HS is diagnosed by clinicians recognising the condition.
?????????????
doi : 10.1111/bjd.19586
Volume183, Issue6 December 2020 Pages e196-e196
?????????????????????? 2% ???????????????????????????????????????????????????????????????????????????????????????
????????????????????????????????????????
doi : 10.1111/bjd.19587
Volume183, Issue6 December 2020 Pages e197-e197
??????????????????????????????? 3% ??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
1985 ?? 2015 ?? 31 ???/??????????
doi : 10.1111/bjd.19588
Volume183, Issue6 December 2020 Pages e198-e198
?????????????????????????? 86% ?????????????????/??????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????
doi : 10.1111/bjd.19589
Volume183, Issue6 December 2020 Pages e199-e199
????? (AE) ????????????????1?5% ????????????????????????????? AE ????????
???????????????
doi : 10.1111/bjd.19590
Volume183, Issue6 December 2020 Pages e200-e200
?????????? HS?????????????????????????????????????????? HS ??????????????????????
